Replies to post #566859 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

"Eight of the 232 patients (3.4%) receiving DCVax-L were treated with tumor-treating fields (TTF) following recurrence. Four of those 8 patients (50.0%) continued receiving DCVax-L while using the TTF device after recurrence and survived from 22.6 to more than 72.7 months from randomization. Four of the 8 patients (50.0%) stopped receiving DCVax-L while using the TTF device post-recurrence, and survived from 8.9 to 29.2 months from randomization."

What does this tell you?

[sentiment_stocks]

Yes but it was run as a randomized, double arm trial and so incurred none of the bias that might be found in a trial that began and ended as a single arm trial.

Surely your mind a nimble enough to understand the difference, right?